Aprea Therapeutics (APRE) Q2 2026 earnings

Published Aug 12, 2026

AI summary

GAAP EPS −$0.07 beat the −$0.23 consensus by $0.16, up from −$0.53 a year ago.
Aprea reported no grant revenue for the second quarter of 2026 compared to $118,111 in the prior year period.
The company recorded a net loss of $3.6 million for the quarter, resulting in a loss of $0.07 per share.
Research and development expenses rose to $2.5 million, driven by the ongoing ACESOT-1051 clinical trial.
Aprea ended the quarter with $41.2 million in cash and cash equivalents to fund operations into early 2028.

Revenue

Not reported in this release.

EPS · GAAP (street basis)

Reported · Diluted EPS (GAAP, street basis)

−$0.07

Consensus −$0.23

Beat by $0.16

GAAP EPS: −$0.07

Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.

No guidance in this release.

The company has no current revenue streams and is entirely focused on clinical-stage development.
The ABOYA-119 clinical trial was closed to prioritize resources for the APR-1051 program.

Source: Aprea Therapeutics, Inc. press release · SEC Form 8-K exhibit 99.1

Figures as stated in the company’s release; consensus from the provider named above. Not financial advice.